Soligenix(US:SNGX) Prnewswire·2024-09-16 11:30Core Insights - Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs, inviting investors to a webinar on September 18, 2024 [1][2] Company Overview - The company is developing several product candidates in advanced clinical stages, targeting a potential $2 billion in annual global sales [2] - Key product HyBryte™ (synthetic hypericin) is a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), showing positive results in a Phase 3 study and preparing for a follow-up Phase 3 study [2][4] - HyBryte™ has an estimated market potential of approximately $250 million [2] - Other notable assets include SGX302 for psoriasis, with a market potential exceeding $1 billion, and SGX945 for Behçet's Disease, with a Phase 2a study set to begin later this year [2][4] Public Health Solutions - The company has a Public Health Solutions segment, including a heat-stable vaccine platform technology, ThermoVax®, which has received significant non-dilutive government funding [5] - Development programs include vaccine candidates for ricin toxin, filoviruses (Marburg and Ebola), and COVID-19 [5]